ITP - Immune Thrombocytopenia
Conditions
Keywords
CAR-T, Immune Thrombocytopenia (ITP)
Brief summary
It is a single-center, single-arm, open-labeled clinical trial to evaluate the efficacy and safety of CAR-T cells therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP).
Detailed description
This open label and single-arm study aims to evaluate the efficacy and safety of CAR-T cells therapy in patients with Chronic or Refractory Primary Immune Thrombocytopenia (ITP). After enrollment, a leukapheresis procedure will be performed to manufacture chimeric antigen receptor (CAR) modified T cells. Patients will get a 3-5 days lymphodepletion therapy with fludarabine and cyclophosphamide, then the CAR-T cells will be infused by vein. After infusion, subjects will be followed for safety and efficacy evaluation up to 12 weeks. For those with a durable remission 12 weeks after infusion, the follow-up will last for at least 12 months for disease control.
Interventions
BIOLOGICALCAR-T cells
CAR-T cells will be administered by vein. Before CAR-T infusion，patients will get a 3-5 days lymphodepletion therapy with fludarabine and cyclophosphamide.
Sponsors
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
8 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Willingness to complete the informed consent process and to comply with study procedures and visit schedule; 2. Men and women aged 8-75; 3. Participants diagnosed with chronic (\>12 months duration) or refractory (a documented intolerance or insufficient response to the first and second line standard treatment of ITP) ITP; 4. The results of physical, instrumental, and laboratory examination of patients not suggest any disease which may cause thrombocytopenia other than ITP; 5. Platelet count \<30 x 109 / L; 6. If the patient is taking corticosteroids, the treatment regimen/dose should be stable (at least 2 weeks prior to screening); 7. The results of physical, instrumental, and laboratory examination of patients should be within the normal range or deviations should be regarded by the researcher as clinically insignificant; 8. Willingness to use effective and reliable methods of contraception throughout the entire study period;
Exclusion criteria
1. All subjects with diseases which may cause secondary immune thrombocytopenia 2. Patients with preventive splenectomy; 3. Hemostatic disorders other than chronic thrombocytopenia; 4. Subject treated with drugs that affect platelet function (including but not limited to aspirin, clopidogrel and/or NSAIDs) or anti-coagulants for \> 3 consecutive days within 2 weeks of the study start and until the end of the study; 5. History of platelet agglutination abnormality that prevents reliable measurement of platelet counts; 6. Concurrent malignant disease and/or history of cancer treatment with cytotoxic chemotherapy and/or radiotherapy; 7. Grade III-IV heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other clinically prominent heart disease within one year prior to enrollment; 8. History of thrombosis or presence of significant risk factors for thrombosis; 9. Persons with acute or exacerbation of chronic diseases of the gastrointestinal tract associated with the risk of bleeding, acute infectious diseases, pathologies of the respiratory system; 10. Any clinically significant hepatic impairment (increase of serum transaminase levels by more than 3 times the upper limit of normal); 11. Serum creatinine levels are more than two times higher than the upper limit of normal for a given age and sex; 12. Any other concomitant decompensated diseases or acute conditions, the presence of which, according to the researcher, may significantly affect the results of the study; 13. Human immunodeficiency virus (HIV) seropositivity, Hepatitis B surface antigen positive or hepatitis B core antibody positive and HBV-DNA positive, Patients with hepatitis C (HCV-RNA quantitative test results positive), Or the presence of other serious active viral or bacterial infections or uncontrolled systemic fungal infections; 14. Patients with severe history of allergy or allergic constitution; 15. Pregnancy and lactation; 16. History of mental illness and known alcohol/drug addiction; 17. Poor compliance due to physiological, family, social, geographical and other factors, unable to cooperate with the study protocol and follow-up plan; 18. Had undergone other clinical trials in the 4 weeks prior to participating in this trial;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Portion of patients with response (R) | At least 2 weeks after infusion | platelet count\>30x10\^9/L and at least 2-fold increase of the baseline count, confirmed on at least 2 separate occasions at least 7 days apart, and absence of bleeding |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Portion of patients with relapse | At least 2 weeks after infusion | platelet count below 30x10\^9/L or less than 2-fold increase of baseline platelet count or bleeding after treating effectively; platelet counts confirmed on at least 2 separate occasions approximately 1 day apart |
| Time (in days) from treatment start to response (R) | At least 2 weeks after infusion | Time calculated from infusion to the day when the response (R) criteria are achieved |
| Portion of patients with complete response (CR) | At least 2 weeks after infusion | platelet count\>100x10\^9/L, confirmed on at least 2 separate occasions at least 7 days apart, and absence of bleeding |
| Duration (in days) of response (R) | At least 2 weeks after infusion | Time calculated from the day when the response (R) criteria are achieved, to the day when loss of response (R) criteria is achieved |
| Incidence of adverse events(AE) after infusion | Up to 12 months after infusion | The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included. Description, time, classification, and outcome of AE events resulted from the investigational medical product, delivery method, or emergency measures will be recorded in the case report form. |
| Time (in days) from treatment to complete response (CR) | At least 2 weeks after infusion | Time calculated from infusion to the day when the complete response (CR) criteria are achieved |
Countries
China
Contacts
Primary ContactSanbin Wang, Doctor
Outcome results
None listed